HWAM
MRNA icon

Hennion & Walsh Asset Management’s Moderna MRNA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,054
Closed -$204K – 891
2024
Q3 		$204K Sell
3,054
-56
-2% -$5.14K 0.01% 827
2024
Q2 		$369K Sell
3,110
-83
-3% -$10.5K 0.02% 678
2024
Q1 		$340K Sell
3,193
-52
-2% -$5.24K 0.02% 658
2023
Q4 		$323K Sell
3,245
-77
-2% -$6.48K 0.02% 661
2023
Q3 		$343K Buy
3,322
+197
+6% +$22K 0.02% 622
2023
Q2 		$380K Buy
3,125
+574
+23% +$76.6K 0.02% 594
2023
Q1 		$392K Buy
+2,551
New +$421K 0.02% 573
2022
Q4 		– Sell
-32,736
Closed -$3.87M – 795
2022
Q3 		$3.87M Sell
32,736
-1,851
-5% -$281K 0.25% 100
2022
Q2 		$4.94M Sell
34,587
-1,607
-4% -$230K 0.31% 77
2022
Q1 		$6.24M Sell
36,194
-1,303
-3% -$219K 0.33% 72
2021
Q4 		$9.52M Sell
37,497
-3,429
-8% -$1M 0.47% 45
2021
Q3 		$15.8M Sell
40,926
-902
-2% -$333K 0.83% 18
2021
Q2 		$9.83M Buy
41,828
+5,778
+16% +$1.03M 0.52% 35
2021
Q1 		$4.72M Buy
+36,050
New +$5.22M 0.28% 90

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Hennion & Walsh Asset Management's MRNA Position: Q4 2024 in Review

Hennion & Walsh Asset Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,054 shares — an estimated $204K sold.

Hennion & Walsh Asset Management first reported a position in MRNA in Q1 2021 and held it in 14 quarters. The position peaked at $15.8M in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Hennion & Walsh Asset Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 3,054 Moderna shares in Q4 2024, an estimated $204K.
  • Hennion & Walsh Asset Management first reported a position in Moderna in Q1 2021 and held it in 14 quarters.
  • Hennion & Walsh Asset Management's Moderna position peaked at $15.8M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2024, filed 15 Jan 2025.